NCT02354261View on ClinicalTrials.gov

Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

August 7, 2015

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Basal Cell Carcinoma in Basal Cell Nevus Syndrome
Interventions
DRUG

SUBA-Itraconazole

Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily.

Trial Locations (5)

11733

Stony Brook University, East Setauket

17033

Penn State Hershey Medical Center, Hershey

32174

Ameriderm Research, Ormond Beach

48034

Grekin Skin Institute, Warren

92056

Dermatology Specialists, Inc, Oceanside

Sponsors
All Listed Sponsors
lead

HedgePath Pharmaceuticals, Inc.

INDUSTRY